echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cancers: Efficacy and safety of radiotherapy combined with S-1 in the treatment of head and neck tumors: from a Meta analysis

    Cancers: Efficacy and safety of radiotherapy combined with S-1 in the treatment of head and neck tumors: from a Meta analysis

    • Last Update: 2021-06-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor, accounting for about 3.
    3% of all cancer cases
    .


    Squamous cell carcinoma of the head and neck is generally treated with concurrent radiotherapy and chemotherapy after surgery, and traditional chemotherapy drugs often cause a variety of side effects


    Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor, accounting for about 3.


    Research searches the PubMed, Web of Science, Embase, and Cochrane databases until February 10, 2021
    .


    The random effects model was used to evaluate the tumor response, local control rate (LCR), overall survival (OS) and adverse events (AEs) of S-1 combined with radiotherapy for HNSCC


    Research searches the PubMed, Web of Science, Embase, and Cochrane databases until February 10, 2021


    research summary

     research summary

    The objective response rate (ORR) can be extracted from 6 studies, and the comprehensively calculated ORR is 86.
    3% (95%CI, 60.
    3-96.
    3; I 2 = 85.
    2, p <0.
    001)
    .


    Analysis of the location of the primary tumor showed that the ORR of oral cancer and laryngeal cancer was significantly different (46% vs 97%, I 2 = 67.


    The objective response rate (ORR) can be extracted from 6 studies, and the comprehensively calculated ORR is 86.


    ORR, CBR and LCR-3

    ORR, CBR and LCR-3

    Oral cancer and laryngeal cancer ORR, CBR, LCR-3, OS-3 and grade 3/4 adverse events

    Oral cancer and laryngeal cancer ORR, CBR, LCR-3, OS-3 and grade 3/4 adverse events

    12 studies can calculate the 3-year OS, and the comprehensive 3-year OS is 84.
    0% (95% CI, 71.
    4-91.
    7; I 2 = 79.
    6, p <0.
    001)
    .


    There was a statistically significant difference in OS-3 between oral cancer and laryngeal cancer (60.


    12 studies can calculate the 3-year OS, and the comprehensive 3-year OS is 84.


               OS-3 and grade 3/4 adverse events

    OS-3 and grade 3/4 adverse events

    In summary, the meta-analysis showed that S-1 combined with radiotherapy for head and neck tumors showed good tumor remission and survival, especially in laryngeal cancer, and the toxicity was tolerable
    .


    Therefore, it is necessary to carry out a large randomized controlled study (RCT) to confirm the efficacy and safety of the combination of the two


    In summary, the meta-analysis showed that S-1 combined with radiotherapy for head and neck tumors showed good tumor remission and survival, especially in laryngeal cancer, and the toxicity was tolerable


    Original source:

    Shih, H.


    Shih, H.
    -S.
    ; J hou, H.
    -J.
    ; Ou, Y.
    -H.
    ; et al.
    The Efficacy and Adverse Events in Patients with Head and Neck Cancer Following Radiotherapy Combined with S-1 Therapy: A Meta-Analysis.
    Cancers 2021, 13, 2971.
    https://doi.
    org/ 10.
    3390/cancers13122971.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.